The FDA clears ProlivRx at-home neuromodulation for adjunctive major depressive disorder treatment in adults with inadequate antidepressant response.

Johnson & Johnson’s (J&J) Caplyta (lumateperone) plus antidepressants nearly doubled the likelihood of remission after six ...

A recent study conducted in Norway suggests that MDMA-assisted therapy may provide lasting relief for individuals suffering from major depressive disorder. The findings indicate that the clinical ...

Johnson & Johnson today announced a new analysis of Phase 3 data which found CAPLYTA® (lumateperone), in combination with an antidepressant, showed significantly greater remission rates in adults with ...

For individuals with major depressive disorder (MDD) that does not respond to pharmacotherapy, recent decisions by the U.S.

Depression is one of the most widespread mental health disorders worldwide, affecting approximately 4% of the global ...

Gilgamesh Pharma, a clinical-stage neuroscience company focused on transforming psychiatric treatment, today announced positive topline results from its Phase 2a study of blixeprodil (GM-1020).

BrainsWay’s strategic investment in Neurolief paved the way for the first and only FDA approved at-home neuromodulation ...

Intra-Cellular Therapies’ surging antipsychotic Caplyta has scored again with remarkable trial results, fueling its bid for a third and potentially most lucrative indication—major depressive disorder ...

The approval of medicines called second-generation antipsychotics has allowed major depressive disorder (MDD) and other conditions linked to it to be treated. A person with MDD is usually prescribed ...

Metabolic dysregulation has been implicated in major depressive disorder (MDD), but the causal relationship between plasma ...